A compound with tissue-specific estrogen agonist and estrogen antagonist activity may be termed a selective estrogen receptor modulator (SERM). In postmenopausal women, the SERMs tamoxifen and raloxifene preserve bone, lower circulating LDL levels, but do not treat (and may aggravate) vasomotor symptoms in some women. Tamoxifen has a well-established estrogen antagonist action on the breast, but slightly increases a woman's risk of endometrial cancer. Raloxifene appears to act as an estrogen antagonist for the breast and the endometrium. Preliminary data suggests that some phytoestrogens share characteristics of these SERMs.
|Original language||English (US)|
|Number of pages||21|
|Journal||Infertility and Reproductive Medicine Clinics of North America|
|State||Published - Apr 26 1999|
ASJC Scopus subject areas
- Obstetrics and Gynecology